Education
About Us
Working with TipRanks
Follow Us
Dyne Therapeutics (DYN)
NASDAQ:DYN
DYN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.72 - $47.45
Previous CloseN/A
Volume117.44K
Average Volume (3M)1.71M
Market Cap
$1.27B
Enterprise Value$1.79B
Total Cash (Recent Filing)$435.45M
Total Debt (Recent Filing)$23.99M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
May 01, 2025EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.35
Shares Outstanding113,121,360
10 Day Avg. Volume1,925,376
30 Day Avg. Volume1,711,664
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.23
Forecast
1Y Price Target
$49.17Price Target Upside336.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
Clinical Data And SafetyUpdated Ph1/2 DELIVER data for DYNE-251 in DMD continue to show long-term functional benefits with no new safety signals.
Regulatory ApprovalAn accelerated-approval pathway would strengthen DYNE competitiveness in DM1, driving upside.
Valuation And Market PotentialDYN is seen as undervalued, especially given '251 potential approval with peak sales of $550M.
Bears Say
Regulatory Approval CompetitionThe traditional-approval pathway would imply a DYNE-101 approval behind competitor Avidity and can drive downside.
Regulatory UncertaintyDYN is under significant pressure mainly due to lack of clarity around DYNE-101 regulatory pathway.
Safety And Tolerability ConcernsPotential safety risks associated with TfR1-targeting include anemia, hemorrhage, and kidney injury.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
DYN FAQ
What was Dyne Therapeutics’s price range in the past 12 months?
Dyne Therapeutics lowest stock price was $10.72 and its highest was $47.45 in the past 12 months.
What is Dyne Therapeutics’s market cap?
Dyne Therapeutics’s market cap is $1.27B.
When is Dyne Therapeutics’s upcoming earnings report date?
Dyne Therapeutics’s upcoming earnings report date is May 01, 2025 which is in 34 days.
How were Dyne Therapeutics’s earnings last quarter?
Dyne Therapeutics released its earnings results on Feb 27, 2025. The company reported -$0.88 earnings per share for the quarter, beating the consensus estimate of -$0.936 by $0.056.
Is Dyne Therapeutics overvalued?
According to Wall Street analysts Dyne Therapeutics’s price is currently Undervalued.
Does Dyne Therapeutics pay dividends?
Dyne Therapeutics does not currently pay dividends.
What is Dyne Therapeutics’s EPS estimate?
Dyne Therapeutics’s EPS estimate is -0.85.
How many shares outstanding does Dyne Therapeutics have?
Dyne Therapeutics has 113,121,360 shares outstanding.
What happened to Dyne Therapeutics’s price movement after its last earnings report?
Dyne Therapeutics reported an EPS of -$0.88 in its last earnings report, beating expectations of -$0.936. Following the earnings report the stock price went down -4.496%.
Which hedge fund is a major shareholder of Dyne Therapeutics?
Currently, no hedge funds are holding shares in DYN
---
Dyne Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.17 (336.68% Upside)
$49.17 (336.68% Upside)
Blogger Sentiment
Bullish
DYN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 777.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 9.1%
Last 30 Days ▼ 9.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.95%
12-Months-Change
Fundamentals
Return on Equity
-88.03%
Trailing 12-Months
Asset Growth
318.72%
Trailing 12-Months
Company Description
Dyne Therapeutics
Dyne Therapeutics (DYN) is a biotechnology company focused on developing targeted therapies for patients with genetically driven diseases. The company specializes in advancing innovative treatments for rare muscle disorders, leveraging its proprietary FORCE platform to deliver nucleic acid therapeutics precisely to muscle tissue. Dyne's pipeline includes programs aimed at treating conditions such as Duchenne muscular dystrophy, myotonic dystrophy type 1, and facioscapulohumeral muscular dystrophy.
---
DYN Stock 12 Month Forecast
Average Price Target
$49.17
▲(336.68% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
PTC Therapeutics
―
Best Analysts Covering DYN
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
+40.77%
reiterated a buy rating 12 days ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +40.77% per trade.
---